| Title |
Tyrosine Kinase Inhibitor Tyrphostin AG490 Retards Chronic Joint Inflammation in Mice
|
|---|---|
| Published in |
Inflammation, January 2014
|
| DOI | 10.1007/s10753-014-9820-6 |
| Pubmed ID | |
| Authors |
Valeriya Gyurkovska, Tsvetanka Stefanova, Petya Dimitrova, Svetla Danova, Rositsa Tropcheva, Nina Ivanovska |
| Abstract |
Tyrphostin AG490 is a Janus kinase (JAK) 2 inhibitor that is clinically used as an anticancer agent and is also effective in various models of inflammatory and autoimmune diseases. In this study, we examined the effects of tyrphostin AG490 on the development of collagenase-induced osteoarthritis (CIOA). Our results showed that tyrphostin-ameliorated cartilage and bone destructions. This effect was associated with decreased expression of signal transducers and activators of transcription 3 (STAT3), phosphorylated JAK2, Dickkopf homolog 1, and receptor activator of nuclear factor κB ligand (RANKL) in the joints of arthritic mice. Tyrphostin AG490 suppressed STAT3 phosphorylation and the expression of tumor necrosis factor-related apoptosis-inducing ligand and RANKL by synovial fluid cells. The drug inhibited RANKL-induced osteoclast differentiation in vitro. Molecules, such as tyrphostin AG490 that limit bone erosion and influence osteoclast generation, might have therapeutic utility in joint degenerative disorders. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Bulgaria | 1 | 8% |
| Unknown | 12 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor > Associate Professor | 3 | 23% |
| Researcher | 3 | 23% |
| Unspecified | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Other | 1 | 8% |
| Other | 2 | 15% |
| Unknown | 2 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 5 | 38% |
| Agricultural and Biological Sciences | 2 | 15% |
| Medicine and Dentistry | 2 | 15% |
| Chemistry | 1 | 8% |
| Unspecified | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 2 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2015.
All research outputs
#4,004,036
of 22,741,406 outputs
Outputs from Inflammation
#59
of 1,046 outputs
Outputs of similar age
#48,758
of 308,137 outputs
Outputs of similar age from Inflammation
#2
of 25 outputs
Altmetric has tracked 22,741,406 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,046 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.